Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.74 |
| ▸ | FECH | P22830 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306783 | 1.00 | CHEK1 (0.74) | CHEK1FECHKCNH2EPHA2CHEK2 | |
| SCHEMBL304760 | 0.93 | CHEK1 (0.74) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL305349 | 0.93 | CHEK1 (0.74) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL304759 | 0.93 | CHEK1 (0.74) | CHEK1FECHKCNH2CHEK2AKT1 | |
| SCHEMBL12534406 | 0.91 | CHEK1 (0.76) | CHEK1FECHKCNH2CHEK2 | |
| SCHEMBL305243 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2EPHA2 | |
| SCHEMBL305499 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2 | |
| SCHEMBL304856 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2 | |
| SCHEMBL304855 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2 | |
| SCHEMBL305244 | 0.89 | CHEK1 (0.79) | CHEK1FECHKCNH2EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1869020-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | CHEK1 1/4885FECH 2006/4885KCNH2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.